| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Douglas Richard serves as a Director at MXCT and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 13 buys and 0 sells. Those positions are worth an estimated $273K at current prices.
Historically, Douglas Richard's trades have earned a below-average insider score of 32/100 across 3 rated trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -23.7%.
The biggest single holding is ALDX (~$273K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 195,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | ALDX Aldeyra Therapeutics, Inc. | Director | Buy | 70,000 | $1.40 | $98,000.00 | +56.0% | 0.0% | - | |
| Aug 13, 2025 | MXCT Maxcyte, Inc. | - | Buy | 80,000 | $1.39 | $111,040.00 | +53.1% | +12.3% | +0.7% | |
| Mar 29, 2023 | MXCT Maxcyte, Inc. | Director | Buy | 80,000 | $4.32 | $345,480.00 | +400.0% | +0.5% | -5.0% | |
| Nov 22, 2021 | MXCT Maxcyte, Inc. | Director | Buy | 20,000 | $11.12 | $222,400.00 | New | -41.4% | -42.4% | |
| Mar 16, 2020 | ALDX Aldeyra Therapeutics, Inc. | Director | Buy | 40,000 | $2.75 | $110,000.00 | +47.1% | - | - | |
| Sep 13, 2019 | ALDX Aldeyra Therapeutics, Inc. | Director | Buy | 5,000 | $6.00 | $30,000.00 | +6.3% | - | - | |
| Sep 12, 2019 | ALDX Aldeyra Therapeutics, Inc. | Director | Buy | 20,000 | $5.89 | $117,805.00 | +33.3% | - | - | |
| Sep 10, 2019 | ALDX Aldeyra Therapeutics, Inc. | Director | Buy | 20,000 | $5.00 | $99,963.00 | +50.0% | - | - | |
| May 11, 2017 | NVAX Novavax Inc | Director | Buy | 200,000 | $0.93 | $185,780.00 | +57.1% | - | - | |
| Feb 17, 2017 | ALDX Aldeyra Therapeutics, Inc. | Director | Buy | 40,000 | $4.50 | $180,000.00 | New | - | - |